Roche agrees on $46.8 billion for Genentech
This article was originally published in Scrip
Executive Summary
Roche has finally settled on $46.8 billion, or $95 per share, to acquire the remaining 44.2% of Genentech that it does not own. The friendly merger agreement signed today ends months of tense negotiations and cools the increasingly hostile nature of the takeover.